All In Biotech

Drug Trial Radar · NCT07909031

CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

A Phase 1/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

219

Planned (sponsor's estimate)

Start

Oct 21, 2026

Primary completion

Oct 2028

Study completion Jan 2029

Sponsor

Lead sponsor
Crescent Biopharma, Inc.Industry
Sponsor type
Industry
First posted
Nov 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety and tolerability of monotherapy CR-002 and to identify the MTD and/or optimal biologic dose and RP2D(s) in participants with locally advanced or metastatic solid tumors.

Conditions

  • Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
  • Gastric/GEJ
  • Biliary Tract Cancer (BTC)
  • Esophageal Squamous Cell Carcinoma (ESCC)
  • Ovarian Cancer
  • Endometrial Cancer
  • Cervical Cancer Metastatic
  • Non-small Cell Lung Cancer (NSCLC)

Interventions

  • CR-002Drug

    Intravenous Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Dose Escalation - incidence and nature of dose-limiting toxicitiesTime frame: From the first dose of study drug up until approximately 1 month
  2. Part 1: Dose Escalation - characterization of the maximum tolerated dose, if applicableTime frame: From the first dose of study drug up until approximately 1 month
  3. All Parts - incidence, nature, and severity of treatment emergent adverse events (TEAEs) and treatment emergent serious adverse eventsTime frame: From the first dose of study drug until 90 days after the last dose of study drug
  4. All Parts - incidence and severity of TEAEs leading to dose modificationsTime frame: From the first dose of study drug until 90 days after the last dose of study drug
  5. All Parts - incidence and severity of TEAEs leading to treatment discontinuationTime frame: From the first dose of study drug until 90 days after the last dose of study drug

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Study Site

    Austin, Texas · Recruiting

  • Clinical Study Site

    Dallas, Texas · Recruiting

  • Clinical Study Site

    Fairfax, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.